Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer

Ping Zhao, Jian Sun, Xinwei Huang, Xiangwu Zhang, Xin Liu, Rong Liu, Guangshi Du, Wenqiang Gan, Chuanyu Yang, Yiyin Tang, Ceshi Chen, Dewei JiangInternational Journal of Biological Sciences 2023 · DOI

TL;DR

This study identifies a critical signaling axis, KLF5-EphA2, that drives cancer stemness and chemoresistance in basal-like breast cancer (BLBC). Targeting this axis, particularly by inhibiting EphA2 phosphorylation, shows promise in overcoming treatment resistance and improving therapeutic outcomes in BLBC.

What Problem Does This Paper Address?

Basal-like breast cancer (BLBC) is an aggressive subtype characterized by high heterogeneity, poor prognosis, and frequent recurrence and metastasis, often linked to treatment failure due to chemotherapy resistance. While cancer stem cells (CSCs) are known to contribute to these challenges, the specific molecular mechanisms driving stemness and chemoresistance in BLBC remain incompletely understood. This paper aims to elucidate the role of the EphA2 receptor tyrosine kinase in BLBC stemness and chemoresistance and to identify upstream regulators and potential therapeutic targets.

Methods

The researchers employed a multi-pronged approach combining in vitro and in vivo experiments with clinical data analysis. Key techniques included:

  • Gene knockdown and overexpression: Using siRNA and lentiviral vectors to manipulate KLF5 and EphA2 expression in BLBC cell lines (HCC1937 and HCC1806).
  • Western blotting: To assess protein levels of KLF5, EphA2, and phosphorylated EphA2 (pS897).
  • Flow cytometry: To quantify cancer stem cell markers like ALDH+ and CD44+/CD24- populations.
  • Mammosphere formation assays: To evaluate the self-renewal capacity of BLBC cells, a hallmark of stemness.
  • Chromatin immunoprecipitation (ChIP) and ChIP-qPCR: To investigate the direct binding of KLF5 to the EphA2 promoter.
  • Dual luciferase reporter assays: To confirm the transcriptional regulation of EphA2 by KLF5.
  • Tumor xenograft models: Using nude mice to assess the in vivo efficacy of therapeutic interventions.
  • Clinical sample analysis: Immunohistochemistry (IHC) and database analysis (bc-GenExMiner, TCGA) to correlate KLF5 and EphA2 expression with patient outcomes and tumor subtypes.
  • Pharmacological inhibition: Using the EphA2 inhibitor ALW-II-41-27 to assess its impact on stemness and chemoresistance.

Datasets

The study utilized the following datasets:

  • Clinical samples: Breast cancer patient samples from the Third Affiliated Hospital of Kunming Medical University.
  • Public databases:
    • bc-GenExMiner v4.5 for correlation analysis of EphA2 and KLF5 expression in breast cancer patients.
  • TCGA (The Cancer Genome Atlas) for EphA2 expression analysis in BLBC.
  • GTEx (Genotype-Tissue Expression) for normal mammary tissue data.
  • A cohort (GSE32646_GPL570) for analyzing EphA2 expression in BLBC patients with pathological complete remission (pCR) versus residual disease (RD) post-neoadjuvant chemotherapy (NCT).

Key Insights and Ideas

  • KLF5 is a direct transcriptional regulator of EphA2 in BLBC: The study provides strong evidence, including ChIP-qPCR and luciferase assays, that KLF5 binds to the EphA2 promoter and upregulates its expression. This establishes a direct molecular link between these two key players.
  • TNF-α drives stemness via the KLF5-EphA2 axis: The inflammatory factor TNF-α, known to promote stemness, was shown to induce KLF5 expression, which in turn upregulates EphA2. This suggests that inflammatory signals can prime BLBC cells for stem-like properties through this pathway.
  • EphA2 phosphorylation at S897 is crucial for chemoresistance: The study highlights that phosphorylation of EphA2 at serine 897 (EphA2 pS897) is induced by chemotherapy agents (PTX/DDP) and TNF-α, and this specific modification is critical for conferring chemoresistance.
  • Targeting EphA2 phosphorylation overcomes resistance: The EphA2 inhibitor ALW-II-41-27 effectively reduced EphA2 pS897 levels, suppressed cancer stemness in vitro, and significantly sensitized BLBC xenografts to PTX and DDP in vivo. This demonstrates the therapeutic potential of targeting this specific modification.
  • EphA2 pS897 as a clinical predictor: High expression of EphA2 pS897 in clinical BLBC samples correlated with a poorer response to neoadjuvant chemotherapy, suggesting its utility as a biomarker for predicting treatment outcomes.

Key Results

  • Knockdown of EphA2 significantly reduced the proportion of ALDH+ and CD44high/CD24low cells, and decreased mammosphere formation in BLBC cell lines.
  • KLF5 knockdown decreased EphA2 mRNA and protein levels, while KLF5 overexpression increased them.
  • TNF-α treatment increased both KLF5 and EphA2 expression, and this effect was abolished by KLF5 knockdown.
  • ALW-II-41-27 treatment significantly inhibited mammosphere formation and ALDH+ cell ratios in PTX/DDP-treated BLBC cells.
  • ALW-II-41-27 treatment reduced the IC50 values of PTX and DDP by more than 40% in BLBC cell lines.
  • In vivo studies showed that the combination of ALW-II-41-27 with PTX or DDP dramatically decreased tumor growth in xenograft models, with no significant toxicity observed.
  • Clinical analysis revealed a positive correlation between EphA2 and KLF5 expression in BLBC patients.
  • High EphA2 pS897 expression was more frequent in chemoresistant BLBC samples compared to chemosensitive ones.

Limitations and Future Work

The authors acknowledge that the downstream mechanisms by which the TNF-α-KLF5-EphA2 axis and activated EphA2 pS897 increase BLBC stemness require further investigation. They also suggest exploring whether the Hippo pathway is involved in EphA2 regulation or function, given its known crosstalk with KLF5 and its role in driving chemoresistance in other cancers. Additionally, the potential for unintended toxic effects when inhibiting EphA2 in normal tissues remains a challenge, necessitating careful dose optimization and targeted delivery strategies. Future work could focus on developing more specific inhibitors or combination therapies that leverage these findings for improved BLBC treatment.

Summary updated

Abstract

Ephrin type-A receptor 2 (EphA2) is a member of the tyrosine receptor kinases, a family of membrane proteins recognized as potential anticancer targets. EphA2 highly expressed in a variety of human cancers, playing roles in proliferation, migration, and invasion. However, whether and how EphA2 regulates basal-like breast cancer (BLBC) cell stemness and chemoresistance has not been revealed. Here, KLF5 was proven to be a direct transcription factor for <i>EphA2</i> in BLBC cells, and its expression was positively correlated in clinical samples from breast cancer patients. The inflammatory factor TNF-α could promote BLBC cell stemness partially by activating the KLF5-EphA2 axis. Moreover, phosphorylation of EphA2 at S897 (EphA2 pS897) induced by TNF-α and PTX/DDP contributes to chemoresistance of BLBC. Furthermore, the EphA2 inhibitor ALW-II-41-27 could effectively reduce EphA2 pS897 and tumor cell stemness <i>in vitro</i> and significantly enhance the sensitivity of xenografts to the chemotherapeutic drugs PTX and DDP <i>in vivo</i>. Clinically, tumor samples from breast patients with less response to neoadjuvant chemotherapy showed a high level of EphA2 pS897 expression. In conclusion, KLF5-EphA2 promotes stemness and drug resistance in BLBC and could be a potential target for the treatment of BLBC.
BibTeX
@article{zhao2023targeting,
  author = {Ping Zhao and Jian Sun and Xinwei Huang and Xiangwu Zhang and Xin Liu and Rong Liu and Guangshi Du and Wenqiang Gan and Chuanyu Yang and Yiyin Tang and Ceshi Chen and Dewei Jiang},
  title = {{Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer}},
  journal = {International Journal of Biological Sciences},
  year = {2023},
  doi = {10.7150/ijbs.82567},
}
Figure